NO20076595L - Behandling av leversykdommer hvor jern spiller en rolle i patogenesen - Google Patents

Behandling av leversykdommer hvor jern spiller en rolle i patogenesen

Info

Publication number
NO20076595L
NO20076595L NO20076595A NO20076595A NO20076595L NO 20076595 L NO20076595 L NO 20076595L NO 20076595 A NO20076595 A NO 20076595A NO 20076595 A NO20076595 A NO 20076595A NO 20076595 L NO20076595 L NO 20076595L
Authority
NO
Norway
Prior art keywords
treatment
pathogenesis
role
liver diseases
iron plays
Prior art date
Application number
NO20076595A
Other languages
English (en)
Inventor
Daniele Alberti
Peter Marks
Hanspeter Nick
Lisa Grace Rojkjaer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20076595L publication Critical patent/NO20076595L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen angår anvendelse av 4-[3,5-bis-(2-hydroksyfenyl)-[1,2,4]-triazol-1-yl]benzosyre (heretter betegnet som "forbindelse I") for fremstilling av farmasøytiske sammensetninger for behandling av leversykdommer hos menneske der jern spiller en rolle i patagonesen, inkludert virussykdommer slik som kronisk hepatitt C, eventuelt i forbindelse med antivirale midler og for behandling av ikke virale sykdommer slik som ikke-alkoholisk steatohepatitt og ikke-alkoholisk fettleversykdom.
NO20076595A 2005-05-31 2007-12-20 Behandling av leversykdommer hvor jern spiller en rolle i patogenesen NO20076595L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68584805P 2005-05-31 2005-05-31
US69280805P 2005-06-22 2005-06-22
US74678606P 2006-05-09 2006-05-09
PCT/US2006/020677 WO2006130532A2 (en) 2005-05-31 2006-05-30 Treatment of liver diseases in which iron plays a role in pathogenesis

Publications (1)

Publication Number Publication Date
NO20076595L true NO20076595L (no) 2007-12-20

Family

ID=37106984

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076595A NO20076595L (no) 2005-05-31 2007-12-20 Behandling av leversykdommer hvor jern spiller en rolle i patogenesen

Country Status (16)

Country Link
US (3) US20080199428A1 (no)
EP (1) EP1893198A2 (no)
JP (2) JP2008542380A (no)
KR (2) KR101174966B1 (no)
AU (1) AU2006252718B2 (no)
BR (1) BRPI0610873A2 (no)
CA (1) CA2608709A1 (no)
CR (1) CR9454A (no)
EA (1) EA014772B1 (no)
IL (1) IL187000A0 (no)
MA (1) MA29542B1 (no)
MX (1) MX2007015085A (no)
NO (1) NO20076595L (no)
SM (1) SMAP200700061A (no)
TN (1) TNSN07447A1 (no)
WO (1) WO2006130532A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
EP1917037A2 (en) * 2005-08-15 2008-05-07 F.Hoffmann-La Roche Ag Peg-ifn alpha and ribavirin for hbv treatment
CA2670313C (en) * 2006-11-29 2013-02-12 Novartis Ag Polymorphic forms of deferasirox (icl670a)
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
US9370528B2 (en) * 2011-03-02 2016-06-21 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
KR102051031B1 (ko) * 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
EP3922246A1 (en) * 2014-03-21 2021-12-15 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB202005054D0 (en) 2020-04-06 2020-05-20 Nemysis Ltd Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for Use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
JP4125011B2 (ja) * 2002-01-22 2008-07-23 株式会社 伊藤園 過剰鉄起因肝障害予防・治療剤及び過剰鉄起因肝障害予防・治療飲食物

Also Published As

Publication number Publication date
JP2013082726A (ja) 2013-05-09
US20100098662A1 (en) 2010-04-22
CA2608709A1 (en) 2006-12-07
IL187000A0 (en) 2008-02-09
AU2006252718B2 (en) 2010-04-15
AU2006252718A1 (en) 2006-12-07
MA29542B1 (fr) 2008-06-02
WO2006130532A3 (en) 2007-11-22
EP1893198A2 (en) 2008-03-05
JP5869469B2 (ja) 2016-02-24
CR9454A (es) 2008-04-16
EA200702384A1 (ru) 2008-06-30
TNSN07447A1 (en) 2009-03-17
US20130109730A1 (en) 2013-05-02
BRPI0610873A2 (pt) 2010-08-03
SMAP200700061A (it) 2007-12-28
US20080199428A1 (en) 2008-08-21
JP2008542380A (ja) 2008-11-27
WO2006130532A2 (en) 2006-12-07
KR20100018057A (ko) 2010-02-16
KR101174966B1 (ko) 2012-08-17
MX2007015085A (es) 2008-01-17
KR20080003933A (ko) 2008-01-08
EA014772B1 (ru) 2011-02-28

Similar Documents

Publication Publication Date Title
TNSN07447A1 (en) Treatment of liver diseases in which iron plays a role in pathogenesis
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
MX2010004673A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
WO2007128086A3 (en) Novel viral replication inhibitor
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
EP2050442A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BONE DISORDERS, FUNCTIONAL FOOD OR HEALTH MEASURES CONTAINING THIS COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION AS AN ACTIVE SUBSTANCE
JP2006511538A5 (no)
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
JP2008540506A5 (no)
NO20084913L (no) Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
MA29922B1 (fr) NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
WO2006108682A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
NO20063858L (no) Antimikrobielle preservativer for oppnaelse av en multidoseformulering ved bruk av beta-cyklodekstriner for flytende doseringsformer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application